PortfoliosLab logo
Tools
Performance Analysis
Risk Analysis
Optimization
Factor Model
See All Tools
Portfolio Analysis
Portfolios
Lazy PortfoliosUser Portfolios
Discussions

Aligos Therapeutics, Inc. (ALGS)

Equity · Currency in USD · Last updated Dec 2, 2023
SummaryFinancials

Company Info

ISINUS01626L1052
CUSIP01626L105
SectorHealthcare
IndustryBiotechnology

Highlights

Market Cap$1.31B
EPS$9.35
PE Ratio7.63
PEG Ratio-14.47
Revenue (TTM)$2.51B
Gross Profit (TTM)$494.21M
EBITDA (TTM)$478.09M
Year Range$54.32 - $128.87
Target Price$89.20
Short %6.72%
Short Ratio2.90

Share Price Chart


Loading data...

Performance

The chart shows the growth of an initial investment of $10,000 in Aligos Therapeutics, Inc., comparing it to the performance of the S&P 500 index or another benchmark. All prices have been adjusted for splits and dividends.


-100.00%-80.00%-60.00%-40.00%-20.00%0.00%20.00%40.00%JulyAugustSeptemberOctoberNovemberDecember
-95.28%
31.89%
ALGS (Aligos Therapeutics, Inc.)
Benchmark (^GSPC)

S&P 500

Compare to other instruments

Search for stocks, ETFs, and funds to compare with ALGS

Aligos Therapeutics, Inc.

Return

Aligos Therapeutics, Inc. had a return of -26.42% year-to-date (YTD) and -27.35% in the last 12 months.


PeriodReturnBenchmark
Year-To-Date-26.42%19.67%
1 month-6.52%8.42%
6 months-41.08%7.29%
1 year-27.35%12.71%
5 years (annualized)N/A10.75%
10 years (annualized)N/A9.87%

Monthly Returns Heatmap


JanFebMarAprMayJunJulAugSepOctNovDec
2023-2.59%-14.07%-8.34%-3.26%-13.24%-19.68%16.67%

Risk-Adjusted Performance

This table presents a comparison of risk-adjusted performance metrics for Aligos Therapeutics, Inc. (ALGS) and S&P 500 (^GSPC). Risk-adjusted metrics are performance indicators that assess an investment's returns in relation to its risk, enabling a more accurate comparison of different investment options.


Sharpe ratioSortino ratioOmega ratioCalmar ratioUlcer Index
ALGS
Aligos Therapeutics, Inc.
-0.33
^GSPC
S&P 500
0.91

Sharpe Ratio

The current Aligos Therapeutics, Inc. Sharpe ratio is -0.33. A negative Sharpe ratio means that the risk-free rate is higher than the portfolio's return. This value does not convey any meaningful information.


Rolling 12-month Sharpe Ratio-0.500.000.501.00JulyAugustSeptemberOctoberNovemberDecember
-0.33
0.91
ALGS (Aligos Therapeutics, Inc.)
Benchmark (^GSPC)

Dividend History


Aligos Therapeutics, Inc. doesn't pay dividends

Drawdowns Chart

The Drawdowns chart displays portfolio losses from any high point along the way.


-100.00%-80.00%-60.00%-40.00%-20.00%0.00%JulyAugustSeptemberOctoberNovemberDecember
-97.99%
-4.21%
ALGS (Aligos Therapeutics, Inc.)
Benchmark (^GSPC)

Worst Drawdowns

The table below displays the maximum drawdowns of the Aligos Therapeutics, Inc.. A maximum drawdown is a measure of risk, indicating the largest reduction in portfolio value due to a series of losing trades.

The maximum drawdown for the Aligos Therapeutics, Inc. was 98.31%, occurring on Nov 14, 2023. The portfolio has not yet recovered.


Depth

Start

To Bottom

Bottom

To Recover

End

Total

-98.31%Jan 21, 2021710Nov 14, 2023
-22.62%Nov 17, 202010Dec 1, 20208Dec 11, 202018
-20.62%Dec 24, 20204Dec 30, 20209Jan 13, 202113
-11.11%Oct 19, 20202Oct 20, 20201Oct 21, 20203
-10.79%Nov 10, 20201Nov 10, 20203Nov 13, 20204

Volatility Chart

The current Aligos Therapeutics, Inc. volatility is 27.50%, representing the average percentage change in the investments's value, either up or down over the past month. The chart below shows the rolling one-month volatility.


0.00%10.00%20.00%30.00%40.00%JulyAugustSeptemberOctoberNovemberDecember
27.50%
2.79%
ALGS (Aligos Therapeutics, Inc.)
Benchmark (^GSPC)